The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
Abstract
IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk. OBJECTIVE: To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events. DESIGN: We conducted a nested case-control analysis of a retrospective cohort study. We compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors. SETTING: Health care databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million. PARTICIPANTS: All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009. EXPOSURE: New use of an inhaled long-acting β-agonist or long-acting anticholinergic. MAIN OUTCOME AND MEASURES: An emergency department visit or a hospitalization for a cardiovascular event. RESULTS: Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event. Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]). We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]). CONCLUSIONS AND RELEVANCE: Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Cited by
Papi, A., Vestbo, J., Fabbri, L., Corradi, M., Prunier, H., Cohuet, G., Guasconi, A., Montagna, I., Vezzoli, S., Petruzzelli, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30206-x · Cited by 603
Cardiovascular disease and COPD: dangerous liaisons?
Rabe, K. F., Hurst, J. R., & Suissa, S. (2018) · European Respiratory Review · doi:10.1183/16000617.0057-2018 · Cited by 410
Defining the relationship between COPD and CVD: what are the implications for clinical practice?
Morgan, A. D., Zakeri, R., & Quint, J. K. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750524 · Cited by 337
Gershon, A. S., Campitelli, M. A., Croxford, R., Stanbrook, M. B., To, T., Upshur, R., Stephenson, A. L., & Stukel, T. A. (2014) · JAMA · doi:10.1001/jama.2014.11432 · Cited by 121
Self-citationRelative and absolute lung function change in a general population aged 60-102 years
Luoto, J., Pihlsgård, M., Wollmer, P., & Elmståhl, S. (2019) · European Respiratory Journal · doi:10.1183/13993003.01812-2017 · Cited by 47
Metadata
- Authors
- Gershon, A., Croxford, R., Calzavara, A., To, T., Stanbrook, M. B., Upshur, R., & Stukel, T. A.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2013-07-08
- Volume
- 173
- Issue
- 13
- Pages
- 1175
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2014032502
- Cited by
- 184
- References
- 1
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.